Case Report Complete author article information provided references Kidney Med 32286293 Published online January 19 2021 doi 101016 jxkme202010011 TAFRO Syndrome With Kidney Involvement A Case Series Patients With Kidney Biopsies Keiki Shimada Takaya Sasaki Masahiro Okabe Kentaro Koike Daisuke Takahashi Risa Terashima Yu Honda Naoto Matsumoto Akira Fukui Masahiro Ishikawa Nobuo Tsuboi Takashi Yokoo fever reticulin myeloﬁbrosisrenal insufﬁciency organo TAFRO thrombocytopenia anasarca megaly syndrome systemic inﬂammatory disease sharing features Castleman disease POEMS polyneuropathy organomegaly endocrinopathy monoclonal protein skin changes syndrome relation abnormal secretions interleukin 6 vascular endothelial growth factor The kidney main target organ TAFRO syndrome kidney histopathology associated TAFRO syndrome completely deﬁned We report 3 TAFRO syndrome cases different clinical courses kidney biopsies performed In 3 cases kidney biopsies showed similar glomerular lesions diffuse global swelling endothelium expansion subendothelial injury Case 3 showed additional ﬁnding spaces consistent severe glomerular endothelial focal tubulointerstitial injury characterized marked plasma cell inﬁltration absent 2 cases Clinical symptoms cases 1 2 lower disease severity scores TAFRO syndrome effectively treated administration corticosteroids combination cor ticosteroids cyclosporine A Case 3 higher disease severity score aggressive clinical course refractory corticosteroids tocilizumab patient ultimately died multiple organ failure In 3 cases kidney biopsy provided indications diagnosis process clinical management TAFRO syndrome 2021 The Authors Published Elsevier Inc behalf National Kidney Foundation Inc This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 fever F INTRODUCTION TAFRO syndrome lifethreatening systemic inﬂam matory disorder characterized thrombocytopenia T anasarca A reticulin myeloﬁbrosisrenal insufﬁciency R organomegaly O Patients TAFRO syndrome exhibit acute progressive critical clinical courses1 The clinical symptoms TAFRO syndrome similar patients idiopathic multicentric Castleman disease shows lymphadenopathy hepatosplenomegaly pancyto penia Excessive production interleukin 6 IL6 vascular endothelial growth factor VEGF induce endothelial cell injury vascular permeability respec tively involved pathogenesis progres sion organ damage TAFRO syndrome Castleman disease The kidney wellknown target organ TAFRO syndrome However kidney histopathologic ﬁndings TAFRO syndrome sufﬁciently described severe thrombocytopenia occasionally occurs making difﬁcult perform kidney biopsies patients TAFRO syndrome Accordingly limited number cases reported relation clinicopathologic correlations patients TAFRO syndrome We report kidney histopathologic ﬁndings 3 cases TAFRO syndrome showed different clinical courses CASE REPORTS Case 1 A man 30s referred 1month history fatigue He presented hypertension blood pressure 176117 mm Hg swelling right axillary lymph node edema limbs Laboratory examination showed followimg values platelet count 185000μL serum Creactive protein CRP 116 mgdL serum creatinine Scr 192 mgdL estimated glomerular ﬁltra tion rate eGFR 35 mLmin173 m2 serum IL6 447 pgmL serum VEGF 1510 pgmL Urinalysis showed urinary protein excretion 181 gd red blood cell count urinary sediment 100 cellshighpower ﬁeld Kidney biopsy performed day 2 hospitalization Fig 1AC TAFRO syndrome diagnosed based 3 major 2 minor criteria severity score 5 12 points1 He required hemodialysis acute kidney injury oral corticoste roids serum CRP Scr levels immediately decreased followed platelet count gradually recovering minimal count 26000μL day 26 Fig 2A His platelet count recovered 200000μL 5 months Case 2 A man 50s admitted 1month history lowgrade fever He presented hypertension blood 286 Kidney Med Vol 3 Iss 2 MarchApril 2021 Shimada et al Figure 1 Kidney histopathologic ﬁndings 3 cases TAFRO thrombocytopenia anasarca fever reticulin myeloﬁbrosisrenal insufﬁciency organomegaly syndrome A Glomeruli diffusely enlarged glomerular capillaries globally occluded Arrowheads indicate focal mesangiolysis ballooning glomerular capillary loops case 1 periodic acidsilver methenamine hematoxylin eosin PASMHE staining scale bar 50 μm B Glomerular capillaries occluded enlarged glomerular endothelial cells inﬁltrating cells case 1 PASMHE staining scale bar 20 μm C An interlobular artery occluded thrombus suggesting thrombotic microangiopathy arrow case 1 Masson trichrome staining scale bar 50 μm D Glomerular endothelial cells diffusely enlarged focal mesangiolysis arrowheads observed case 2 PASMHE staining scale bar 50 μm E Electron microscopy showed markedly swollen glomerular endothelial cells arrow occupying glomerular capil lary case 2 scale bar 2 μm F Glomeruli diffusely enlarged glomerular capillaries globally occluded enlarged endothelial cells inﬁltrated cells Arrowheads indicate focal mesangiolysis case 3 PASMHE staining scale bar 50 μm G Focal tubulointerstitial nephritis associated plasma cell inﬁltration case 3 HE staining scale bar 100 μm H Magniﬁed image shows large portions inﬁltrating cells composed plasma cells case 3 HE staining scale bar 50 μm I Electron microscopy showed widening subendothelial space arrows inﬁltration plasma cells arrowheads mesangial areas case 3 scale bar 2 μm Kidney Med Vol 3 Iss 2 MarchApril 2021 287 PSL mgday 60 50 40 30 Shimada et al Hemodialysis Platelet transfusion Kidney biopsy 25 L d g m P R C 20 15 10 5 0 Platelet count Serum CRP Serum creatinine 10 5 0 L d g m e n n t e r C 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 days CsA mgday 300 200 35 30 25 20 Platelet count Serum CRP Serum creatinine PSL mgday 70 Platelet transfusion Kidney biopsy 15 L d g m P R C 10 5 0 3 2 1 0 L d g m e n n t e r C 1 8 15 22 29 36 43 50 57 64 71 78 85 92 99 106 113 120 days 1000 mg Tocilizumab 600 mg 120 mPSL mgday 80 PSL mgday 80 Hemodialysis Platelet transfusion 50 25 0 30 20 10 L d g m P R C 0 1 Kidney biopsy Platelet count Serum CRP Serum creatinine 10 5 0 L d g m e n n t e r C 8 15 22 days A L μ 3 0 1 t n u o c 250 200 150 100 50 0 150 100 50 0 l t e e t P l B L μ 3 0 1 t n u o c l t e e t P l C L μ 3 0 1 t n u o c l t e e t P l Figure 2 Clinical courses 3 TAFRO thrombocytopenia anasarca fever reticulin myeloﬁbrosisrenal insufﬁciency organo megaly syndrome cases kidney involvement Clinical courses separately presented A case 1 B case 2 C case 3 Abbreviations CRP Creactive protein CsA cyclosporine A PSL prednisolone mPSL methylprednisolone 288 Kidney Med Vol 3 Iss 2 MarchApril 2021 Shimada et al pressure 177109 mm Hg moderate edema limbs platelet count 139000μL serum CRP level 954 mgdL Scr level 120 mgdL eGFR 50 mL min173 m2 serum IL6 level 70 pgmL serum VEGF level 783 pgmL Urinalysis showed urinary protein excretion 131 gd signiﬁcant micro scopic hematuria Kidney biopsy performed day 5 hospitalization Fig 1D TAFRO syndrome diag nosed based 3 major 4 minor criteria severity score 5 12 points1 Oral corticosteroids combined cyclosporine A administered result ing gradual improvement platelet count minimal count 12000μL day 75 He dis charged day 118 Fig 2B His platelet count recovered 230000μL 5 months Case 3 A man 50s presented 1week history cough fever He showed high body temperature 388 cid1C moderate edema limbs hypertension admission Laboratory examination showed thrombocy topenia platelet count 30000 μL serum CRP level 265 mgdL Scr level 110 mgdL eGFR 57 mL min173 m2 serum IL6 level 890 pgmL Uri nalysis showed urinary protein excretion 037 gg creatinine signiﬁcant microscopic hematuria Computed tomography showed bilateral pleural effusion ascites enlargement axillary inguinal lymph nodes He acute kidney injury Scr 282 mgdL eGFR 20 mLmin173 m2 required hemodialysis diureticresistant volume overload day 9 hospitalization Fig 2C Kidney biopsy performed day 10 platelet transfusion Fig 1E F TAFRO syndrome diagnosed based 3 major 3 minor criteria severity score 9 12 points1 Cortico steroid therapy improve general condition Hypotension observed day 14 noradrenaline administrated Despite additional treatments intravenous methylprednisolone pulse followed tocili zumab general condition worsened died multiple organ failure day 24 DISCUSSION We presented 3 cases TAFRO syndrome kidney involvement Kidney histopathology 3 cases consistently showed severe glomerular endothelial injury evidenced diffuse global endothelial cell swelling enlarged subendothelial spaces The ﬁndings thrombotic microangiopathy case 1 mesangiolysis cases 1 2 3 identiﬁed biopsies support endothelium especially glomerular endothelium main target kidney injury TAFRO syndrome In addition severe glomerular endothelial injury kidney biopsy case 3 higher disease severity score featured focal tubulointerstitial injury associated plasma cell inﬁltration absent 2 cases lower disease severity scores To knowledge biopsy ﬁndings TAFRO syndrome reported 14 cases including cases suggesting marked glomerular endothelial cell injury Table 1215 consistently demonstrated ﬁndings Castleman disease POEMS polyneuropathy orga nomegaly endocrinopathy monoclonal plasma cell dis order skin changes syndrome considered similar pathologic entities TAFRO syndrome abnormal secretion biological actions IL6 VEGF involved pathogenesis dis eases In animal experiments overproduction IL6 duces endothelial cell injury VEGF known increase vascular permeability16 Approximately 50 40 cases Castleman disease POEMS syndrome respectively glomerular endothelial cell injury1718 Serum IL6 VEGF levels increased patients TAFRO syndrome previously diagnosed1 In cases TAFRO syndrome kidney involvement presented serum IL6 VEGF levels elevated 3 cases 2 cases serum VEGF measured case 3 respectively These ﬁndings consistent hypothesis IL6 andor VEGF responsible kidney involvement TAFRO syndrome mainly attributed glomerular endothelial injury VEGF constitutively secreted podocytes crucially involved development maintenance glomerular endothelium19 Podocytespeciﬁc VEGF conditional knockout mouse models patients preeclampsia undergoing antiVEGF therapy shown glomerular endotherial damage similar present cases TAFRO syndrome1920 In patients preeclampsia increased soluble FLT1 VEGF receptor 1 functions potential antagonist VEGF Although circulating VEGF levels increase patients TAFRO syndrome Castleman disease case reports showed glomerular VEGF expression decreased led glomerular endothelial injury7 This controversial research needed clarify mechanism underlying glomerular endothelial injury TAFRO syndrome tocilizumab Currently ideal treatment strategy patients TAFRO syndrome unestablished Highdose corticoste siltuximab antiIL6 monoclonal roids antibody cytotoxic chemotherapies cyclosporine A commonly therapies result failure relapse21 Case 1 responded treatment corticosteroid monotherapy case 2 effectively treated combination oral corticosteroids cyclosporine A However case 3 refractory intensive therapy including corticosteroids tocilizumab patients serum IL6 level high Similarly cases resis tant tocilizumab therapy reported22 This led assumption humoral factors IL6 involved pathogenesis TAFRO syndrome Kidney Med Vol 3 Iss 2 MarchApril 2021 289 Table 1 Comparison Kidney Histopathologic Findings Treatments Between Reported Cases TAFRO Syndrome Reference Tanaka et al2 2017 Joscid1e et al3 2017 Kawashima et al4 2017 Mizuno et al5 2018 Nakamori et al6 2018 NodaNarita et al7 2018 Age ySex 70male 61female 38male 84male 54female 80female Furuto et al8 2018 55female Ito et al9 2018 76female Light Microscopy Glomerular endothelial cell swelling double contours GBM mesangiolysis interstitial edema Mesangial expansion TMA double contours GBM Mesangial proliferation double contours GBM Glomerular endothelial cell swelling endocapillary hypercellularity mesangiolysis Glomerular endothelial cell swelling mild interstitial inﬂammation Glomerular endothelial cell swelling endocapillary hypercellularity double contours GBM Mesangial proliferation double contours GBM Endocapillary hypercellularity double contours GBM mesangial proliferation massive macrophage inﬁltration glomeruli tubulointerstitial area Noda et al10 2018 79female Double contours GBM mesangiolysis Ozeki et al11 2018 51female Nagayama et al12 2019 48female Glomerular endothelial cell swelling double contours GBM mesangiolysis partial inﬁltration monocytes plasma cells tubulointerstitial lesions Glomerular endothelial cell swelling endocapillary hypercellularity double contours GBM mesangiolysis Immunoﬂuorescence Negative Not performed Electron Microscopy No EDD glomerular endothelial cell swelling enlarged subendothelial spaces Not performed IgA IgM C3 Not performed Negative No EDD glomerular endothelial cell swelling Negative No EDD IgM κ light chain IgM Negative Negative Negative Negative No EDD glomerular endothelial cell swelling enlarged subendothelial spaces No EDD mesangial interposition duplication GBM podocyte foot process effacement No EDD enlarged subendothelial spaces mesangial interposition duplication GBM podocyte foot process effacement No EDD glomerular endothelial cell swelling enlarged subendothelial spaces No EDD glomerular endothelial cell swelling enlarged subendothelial spaces No EDD enlarged subendothelial spaces edematous change mesangial areas podocyte foot process effacement 2 9 0 K d n e y M e d V o l 3 I s s 2 M r c h A p r l 2 0 2 1 Treatment Corticosteroids Response Therapies Effective Corticosteroids tocilizumab rituximab Corticosteroids Corticosteroids tocilizumab plasma exchange Corticosteroids Corticosteroids tocilizumab Effective Effective Effective Effective Effective Corticosteroids Effective Corticosteroids Effective Corticosteroids rituximab plasma exchange Effective Corticosteroids Effective Corticosteroids cyclosporine A tocilizumab Effective Continued S h m d e t l Table 1 Contd Comparison Kidney Histopathologic Findings Treatments Between Reported Cases TAFRO Syndrome Immunoﬂuorescence IgM C1q κ λ light chains Electron Microscopy Subendothelial EDD podocyte foot process effacement Treatment Corticosteroids Response Therapies Effective S h m d e t l Reference Leurs et al13 2019 Age ySex 28female Saito et al14 2019 45female Light Microscopy Glomerular endothelial cell swelling endocapillary hypercellularity double contours GBM mesangial proliferation mesangiolysis Glomerular endothelial cell swelling double contours GBM mesangiolysis Negative Hashimoto et al15 20195 69male Mesangial proliferation double contours GBM IgM C1q Case 1 30smale Case 2 50smale Case 3 50smale Glomerular endothelial cell swelling endocapillary hypercellularity mesangiolysis vascular initial thickening TMA Glomerular endothelial cell swelling endocapillary hypercellularity mesangiolysis Glomerular endothelial cell swelling endocapillary hypercellularity mesangiolysis interstitial nephritis plasma cell inﬁltration Negative Negative Negative No EDD glomerular endothelial cell swelling enlarged subendothelial spaces Subendothelial EDD enlarged subendothelial spaces mesangial proliferation expansion Not performed No EDD glomerular endothelial cell swelling enlarged subendothelial spaces No EDD glomerular endothelial cell swelling enlarged subendothelial spaces podocyte foot process effacement Corticosteroids cyclosporine A Effective Corticosteroids cyclosporine A Not effective Corticosteroids Effective Corticosteroids cyclosporine A Effective Corticosteroids tocilizumab Not effective Abbreviations EDD electrondense deposits GBM glomerular basement membrane IgA immunoglobulin A TAFRO thrombocytopenia anasarca fever reticulin myeloﬁbrosisrenal insufﬁciency organomegaly TMA thrombotic microangiopathy K d n e y M e d V o l 3 I s s 2 M r c h A p r l 2 0 2 1 2 9 1 Treatments targeting humoral factors plasma ex change targeted therapies molecules IL6 considered alternative strategies patients TAFRO syndrome especially showing severe clinical manifestations Consistent idea successful treatment rituximab plasma exchange reported previous case TAFRO syndrome23 fever The factors determine prognosis TAFRO syndrome unknown Disease severity scores TAFRO syndrome based combination thrombocy topenia anasarca reticulin myeloﬁbrosisrenal insufﬁciency organomegaly clinically identiﬁ able ﬁndings1 Despite 3 cases showing severe glomerular endothelial injury determine differences severity glomerular lesions tubulointerstitial injury marked plasma cell inﬁltration identiﬁed case 3 showed higher disease severity score Although tubulointerstitial nephritis involved TAFRO syndrome cases associated poor prognosis6911 report described tubu lointerstitial inﬁltration massive plasma cells Plasma cell inﬁltration kidney implies plasma cells inﬁltrate organs reﬂect severity poor prognosis TAFRO syndrome Instead In summary discussed 3 cases diagnosed TAFRO syndrome patients underwent kidney biopsy showed different clinical courses Lesions indicating severe glomerular endothelial cell injury consistently iden tiﬁed 3 cases Focal tubulointerstitial inﬁltration plasma cells identiﬁed 1 case showed In cases kidney biopsy aggressive clinical course ﬁndings provided useful information supported diagnosis TAFRO syndrome determination treatment strategy Further accumulation cases required elucidate pathophysiologic basis kidney involvement TAFRO syndrome ARTICLE INFORMATION Authors Full Names Academic Degrees Keiki Shimada MD Takaya Sasaki MD Masahiro Okabe MD PhD Kentaro Koike MD PhD Daisuke Takahashi MD Risa Terashima MD Yu Honda MD Naoto Matsumoto MD Akira Fukui MD PhD Masahiro Ishikawa MD PhD Nobuo Tsuboi MD PhD Takashi Yokoo MD PhD Authors Afﬁliations Division Nephrology Hypertension Department Internal Medicine The Jikei University School Medicine Tokyo KS TS MO KK DT RT NM AF NI NT YK Department Nephrology Kawaguchi Municipal Medical Center Kawaguchi Japan KS TS YH MI Address Correspondence Masahiro Okabe MD PhD Division Nephrology Hypertension Department Internal Medicine The Jikei University School Medicine 3258 NishiShimbashi Minatoku Tokyo Japan Email mokabejikeiacjp Support None Financial Disclosure The authors declare relevant ﬁnancial interests Patient Consent The authors declare obtained consent patient reported article relative Shimada et al appropriate authority publication information appears Case Report Peer Review Received May 24 2020 Evaluated 1 external peer reviewer direct editorial input Associate Editor EditorinChief Accepted revised form October 25 2020 REFERENCES 1 Masaki Y Kawabata H Takai K et al Proposed diagnostic criteria disease severity classiﬁcation treatment strategy J Hematol TAFRO syndrome 2015 version 20161036686692 Int 2 Tanaka M Tsujimoto H Yamamoto K et al Clinicopathological features progressive renal involvement TAFRO syndrome case report literature review Medicine Baltimore 20179640e8216 Joscid1e FF Kerbauy LN Perini GF et al A lifethreatening case TAFRO syndrome dramatic response tocilizumab rit uximab pulse steroids Latin America Medicine Baltimore 20179613710 ﬁrst case report 3 4 Kawashima M Usui T Okada H et al TAFRO syndrome 2 literature Mod Rheumatol cases review 201727610931097 5 Mizuno H Sekine A Oguro M et al Renal histology patient TAFRO syndrome case report Hum Pathol 201882 258263 6 Nakamori A Akagaki F Yamaguchi Y et al Nephrotic syn lymphadenopathy systemic Intern Med 2018578 drome thrombocytopenia inﬂammation splenomegaly 11231129 7 NodaNarita S Sumida K Sekine A et al TAFRO syndrome refractory thrombocytopenia responding tocilizumab romiplostim case report CEN Case Rep 201871 162168 8 Furuto Y Hashimoto H Horiuti H et al Membranoproliferative glomerulonephritislike ﬁndings TAFRO syndrome associ ated anterior mediastinal tumor case report Medi cine Baltimore 20189724e11057 Ito S Uchida T Itai H et al Serial manifestation acute kidney injury nephrotic syndrome patient TAFRO syn drome Intern Med 2018572131293133 9 10 Noda Y Saka Y Kato A et al Successful rituximab treatment TAFRO syndrome pathological ﬁndings glomerular endothelial damage Clin Nephrol Case Stud 2018601 1620 11 Ozeki T Tsuji M Yamamoto J et al Thrombotic microangiopathy kidney biopsy patient TAFRO syndrome CEN Case Rep 201872243247 12 Nagayama Y Yamano M Yagame M et al TAFRO syndrome cause glomerular microangiopathy case report literature review BMC Nephrol 201920119 13 Leurs A Gnemmi V Lionet A et al Renal pathologic ﬁndings continuum thrombotic Tafro syndrome microangiopathy membranoproliferative glomerulone phritis A case report literature review Front Immunol 2019101489 14 Saito H Tanaka K Fujiwara M et al Pathological ﬁndings involvement patient TAFRO syn progressive renal drome CEN Case Rep 201984239245 15 Hashimoto K Sano T Honma Y et al An autopsy case TAFRO syndrome membranoproliferative glomerulonephritislike le sions CEN Case Rep 2019814854 292 Kidney Med Vol 3 Iss 2 MarchApril 2021 Shimada et al 16 Garibotto G Soﬁa A Procopio V et al Peripheral tissue release interleukin6 patients chronic kidney diseases Effects endstage renal disease microinﬂammatory state Kidney Int 2006702384390 17 Xu D Lv J Dong Y et al Renal involvement large cohort Chinese patients Castleman disease Nephrol Dial Transplant 201227suppl 3119125 Imai H Yasuda T et al A spectrum clinico 18 Nakamoto Y pathological associated features POEMS syndrome Nephrol Dial Transplant 19991410 23702378 nephropathy 20 Phipps EA Thadhani R Benzing T Karumanchi SA Pre eclampsia pathogenesis novel diagnostics therapies Nat Rev Nephrol 2019155275289 21 van Rhee F Voorhees P Dispenzieri A et al International evidencebased consensus treatment guidelines idiopathic multicentric Castleman disease Blood 2018132202115 2124 22 Simons M Apor E Butera JN et al TAFRO syndrome asso ciated EBV successful triple therapy treatment case literature Case Rep Hematol report review 2016201617 19 Estrada CC Maldonado A Mallipattu SK Therapeutic inhibi tion VEGF signaling associated nephrotoxicities J Am Soc Nephrol 2019302187200 23 Meguri Y Asada N Nakasako Y et al A case report TAFRO syndrome successfully treated immunosuppressive therapies plasma exchange Ann Hematol 2019982537539 Kidney Med Vol 3 Iss 2 MarchApril 2021 293